Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain

Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain

BackgroundTreatment with immune checkpoint inhibitors (ICI) can induce durable responses in cancer patients, but it is commonly associated with serious immune-related side effects. Both effects are suggested to be mediated by CD8+ T-cell infiltration. Whole body CD8+ T-cell distribution can be visua...

Full description

Bibliographic Details
Main Authors:	K. F. Bol, E. Peeters, C. M. L. van Herpen, H. Westdorp, E. H. J. G. Aarntzen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Immunology
Subjects:	PET/CT imaging immune checkpoint inhibitors CD8+ T-cells toxicity melanoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1199282/full

Similar Items

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival
by: Timo E. Schank, et al.
Published: (2021-05-01)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
by: H. S. Gabryś, et al.
Published: (2022-11-01)

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression
by: Sif Homburg, et al.
Published: (2024-02-01)

Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors
by: Elisabetta Maria Abenavoli, et al.
Published: (2023-11-01)

Checkpoint inhibitor-induced sarcoid choroidal granulomas
by: Cindy Ung, et al.
Published: (2020-06-01)

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
by: Alexia Rivas, et al.
Published: (2022-06-01)

Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
by: Dietz H, et al.
Published: (2021-11-01)

Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy
by: Kasper F. Guldbrandsen, et al.
Published: (2017-04-01)

Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age
by: Raffaella Calabretta, et al.
Published: (2021-11-01)

LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma
by: Sandra van Wilpe, et al.
Published: (2021-04-01)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
by: Ho-Seok Sa, et al.
Published: (2022-08-01)

<sup>18</sup>F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital
by: Jean-Baptiste Le Goubey, et al.
Published: (2021-07-01)

Modulation of CD8<sup>+</sup> T Cell Responses by Radiotherapy—Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors
by: Seung Hyuck Jeon, et al.
Published: (2023-11-01)

Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01)

Skin manifestations associated with checkpoint inhibitors
by: Gianluca Nazzaro, et al.
Published: (2022-06-01)

Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors
by: Luca Cassetta, et al.
Published: (2018-04-01)

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
by: David S. Hong, et al.
Published: (2022-08-01)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
by: Justin Tong, et al.
Published: (2022-10-01)

Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
by: Virginia Ferraresi, et al.
Published: (2022-05-01)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
by: Sonja C. S. Simon, et al.
Published: (2020-01-01)

Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors
by: Xiaoyan SI, et al.
Published: (2019-10-01)

The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria
by: Angelo Castello, et al.
Published: (2022-03-01)

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
by: Stefan Schliep, et al.
Published: (2018-01-01)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
by: Kalijn Fredrike Bol, et al.
Published: (2019-10-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
by: Ivana De Risi, et al.
Published: (2022-09-01)

Impact of [<sup>18</sup>F]FDG PET/CT in the Assessment of Immunotherapy-Induced Arterial Wall Inflammation in Melanoma Patients Receiving Immune Checkpoint Inhibitors
by: Shaghayegh Ranjbar, et al.
Published: (2023-05-01)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
by: Víctor Albarrán, et al.
Published: (2022-02-01)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)

Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor
by: Tingting Ge, et al.
Published: (2022-01-01)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
by: Adrian Perdyan, et al.
Published: (2023-07-01)

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
by: Maria Letizia Motti, et al.
Published: (2020-06-01)

Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib
by: Mark W. D. Sweep, et al.
Published: (2023-06-01)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
by: Vanina Vani, et al.
Published: (2020-04-01)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
by: Vera Petrova, et al.
Published: (2023-02-01)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
by: Michele Guida, et al.
Published: (2021-01-01)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
by: Kang Miao, et al.
Published: (2022-07-01)

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
by: Qian Zhang, et al.
Published: (2023-02-01)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
by: Egesta Lopci
Published: (2021-11-01)